Bonnie Wise
Chgo, ILNPI 1871559120
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 37.3% of the total. Reporting peaked in 2022 at $935 and has fallen 76.8% since, to $217 in 2025.
Across 109 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$842
- Hologic Sales And Service, LLC$166
- Mayne Pharma Commercial LLC$154
- Avion Pharmaceuticals$133
- Organon$111
- Therapeuticsmd, Inc.$93
- plus $760 from 17 others
What the payments were for
- Food & beverage$2,22198%
- Education$372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $842 |
| Hologic Sales And Service, LLC | 9 | $166 |
| Mayne Pharma Commercial LLC | 8 | $154 |
| Avion Pharmaceuticals | 5 | $133 |
| Organon | 8 | $111 |
| Therapeuticsmd, Inc. | 5 | $93 |
| Myovant Sciences Inc. | 3 | $85 |
| Merck | 5 | $85 |
| Coopersurgical, Inc. | 5 | $82 |
| Channel Medsystems, Inc. | 2 | $66 |
| Novo Nordisk | 3 | $62 |
| Millicent US Inc | 3 | $62 |
| Astellas Pharma US Inc | 2 | $59 |
| Bayer | 2 | $45 |
| AMAG Pharmaceuticals, Inc. | 2 | $37 |
| BD | 1 | $35 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Boston Scientific | 1 | $29 |
| Pfizer | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Duchesnay USA Incorporated | 1 | $15 |
| Lupin Inc. | 1 | $14 |
| Scynexis, Inc. | 1 | $14 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 11 | $1,793 |
| ValacyclovirValacyclovir Hcl | 11 | $406 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.